Loading...
$8.3M
Awarded Sep 24, 2026
Competition
FULL AND OPEN COMPETITION
Offers
N/A
Set-Aside
None
Solicitation Type
RFP - Negotiated
Program
BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA) PEDIATRIC TRIALS NETWORK (PTN) IDIQ
Performance Timeline
Start
Sep 28, 2026
Estimated start: Sep 27, 2029
Contract: 75N94026F00002
UEI
TP7EK8DZV6N5
Parent Company
DUKE UNIVERSITY
Capabilities & Certifications
Headquarters Location
Congressional District: 04
Current Obligation
$8,301,883
Base + Exercised Options
$8,301,883
Total Ceiling Value
$8,301,883
Contract Type
COST NO FEE
Multi-Year Contract
NO
Description
NICHD: R&D: BESPOKE GENE THERAPY CONSORTIUM (BGTC) - SUPPORT FOR NIH-SPONSORED CLINICAL TRIALS: NON-SEVERABLE
NAICS
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Place of Performance
Congressional District: 04
Awarding Agency
Top-tier Agency
National Institutes of Health
Sub-tier Agency
NATIONAL INSTITUTES OF HEALTH NICHD
Office
Funding Agency
Top-tier Agency
National Institutes of Health
Sub-tier Agency
NATIONAL INSTITUTES OF HEALTH NICHD
Office
Contract Vehicle
75N94025D00003
IDCDepartment of Health and Human Services
Award Type: SINGLE AWARD